Advances in Therapy

Advances in Therapy is published by Springer Healthcare and is in Zone 3 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Diabetes Treatment and Management, Asthma and respiratory diseases and Rheumatoid Arthritis Research and Therapies, together about 21.6% of its articles. Its main subfields are Endocrinology, Diabetes and Metabolism. (generated from OpenAlex topic counts and CAS ranking data)

Aims and Scope Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research. Rapid Publication The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted it will be published online 3-4 weeks from acceptance. Please note that for any steps outside of our standard publication processes, such as multiple rounds of peer review or article proofs, or non-standard copyright requests, this may delay publication beyond these timelines. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid and efficient communication of the latest research and reviews, allowing the advancement of clinical therapies. Personal ServiceThe journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that they

From the journal's Aims & Scope

Research area (LetPub): Pharmacology & Pharmacy

Editorial board by country: 13 in mainland China (about 3%); most named United States 143, Italy 68, United Kingdom 39, Spain 21, Greece 17 (472 members with a country) Editorial board ↗Publisher website · 2026-09-29

CAS Journal Ranking

Database indexing

SCIEScopusLetPub

International journal early-warning lists: not listed in any editionLetPub

Indexing the journal's website claims

MEDLINEEmbaseCASCAB AbstractsCurrent ContentsPublisher website

Other: Google Scholar, EBSCO, ProQuest, Dimensions, CNKI, Baidu, Naver, OCLC, Portico, CLOCKSS, Semantic Scholar

As the journal's website lists them, not checked against each database; for Web of Science editions the records above apply.

Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.

Impact

Impact factor

4.67LetPub · 2026-09-13

Impact factor (publisher) 2025

4.7Publisher website · 2026-09-29

5-year impact factor (publisher) 2025

4.6Publisher website · 2026-09-29

CiteScore 2026-06

7.6LetPub · 2026-09-13

SJR 2026-06

1.42LetPub · 2026-09-13

SNIP 2026-06

1.59LetPub · 2026-09-13

h-index

53LetPub · 2026-09-13

h-index

115OpenAlex · 2026-10-01

i10-index

2,503OpenAlex · 2026-10-01

2-year mean citedness

4.24OpenAlex · 2026-10-01

Self-citation rate

2.1%LetPub · 2026-09-13

Share of gold OA articles

78.29%LetPub · 2026-09-13

Volume

Articles per year

325LetPub · 2026-09-13

Downloads per year (publisher) 2025

3,500,000Publisher website · 2026-09-29

Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.

Other sources

Average review time (community reports)

6–12 weeksLetPub · 2026-09-13

Average acceptance (community reports)

Fairly easyLetPub · 2026-09-13

Submission to first decision

2 daysPublisher website · 2026-09-29

Acceptance to publication

28 daysPublisher website · 2026-09-29

Peer review

Single anonymous peer reviewPublisher website

Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.

A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.

The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.

Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.

Publisher

Springer Healthcare

Country or region

ENGLAND

Language

English

Frequency

Monthly

Founded

2000

ISSN

0741-238X

Electronic ISSN

1865-8652

Latest issue on the website

Volume 43, Issue 9 (September 2026)

Official links

• Journal homepage ↗OpenAlex
• Submission system ↗LetPub
• Author guidelines ↗LetPub
• Special issues ↗Publisher website